{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-053023","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2025-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.118144+00:00","generated_at":"2026-05-23T16:41:18.606168+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Perspective Therapeutics doses first patient in new 1.5 mCi monotherapy cohort for lead TAT candidate","bullets":["First patient dosed in Phase 1/2a trial of [212Pb]VMT01 as monotherapy at 1.5 mCi in MC1R-positive metastatic melanoma.","Cohort includes patients with brain metastases; prior imaging showed tracer uptake in brain lesions.","Combination arm with nivolumab began dosing in March 2025; Fast Track Designation from FDA granted September 2024.","Initial monotherapy results were presented at SMR October 2024; this cohort aims to refine dosing and assess brain metastasis activity."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-053023","json":"https://secwatch.observer/filing/0000950170-25-053023.json","markdown":"https://secwatch.observer/filing/0000950170-25-053023.md","text":"https://secwatch.observer/filing/0000950170-25-053023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000095017025053023/0000950170-25-053023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000095017025053023/catx-20250411.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T16:41:18.606168+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}